ArriVent BioPharma, Inc. Common Stock (AVBP NASDAQ) stock market data APIs
$28.222
-0.26(-0.9%)
as of September 17, 2026
Try our APIs with
free plan!
ArriVent BioPharma, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Prev. Close
28.222
Open
27.9641
High
28.5123
Low
27.9104
52 wk Range
17-35.83
Market Cap
1 363 M
Shares Outstanding
49 308 K
EPS
-1.05
Beta
1.358
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ArriVent BioPharma, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ArriVent BioPharma, Inc. Common Stock data using free add-ons & libraries
Get ArriVent BioPharma, Inc. Common Stock Fundamental Data
ArriVent BioPharma, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get ArriVent BioPharma, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.98
Get ArriVent BioPharma, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ArriVent BioPharma, Inc. Common Stock News
New
Citi's picks and pans for H2 '26: REITs, tech, consumer, health
[Citibank headquarters in Canary Wharf, London, UK] VV Shots Citi released its roadmap for the second half of 2026, including a macro-to-micro view of equity sectors. "Our recently revised S&P 500 (...
EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight
The outlook for the EGFR inhibitor market continues to be highly promising, supported by the increasing adoption of precision medicine in oncology and the broader use of targeted therapies across vari...
The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
The EGFR-NSCLC pipeline possesses some drugs in late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, includ...
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of 2026...
Get ArriVent BioPharma, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
